Last updated: February 12, 2026
What is the current market status of drug NDC 67877-0554?
NDC 67877-0554 corresponds to Tezepelumab (generic name). Approved by the FDA in December 2021 for severe asthma, it marks a significant advancement in biologic treatments targeting eosinophilic and allergic asthma. The drug is marketed under the brand name Tezspire.
Tezspire is a monoclonal antibody that inhibits thymic stromal lymphopoietin (TSLP), a cytokine involved in airway inflammation. It is designated as an orphan drug, which influences its market exclusivity and pricing strategies.
What is Tezspire's current market penetration?
- Pricing: The average wholesale price (AWP) is approximately $6,850 per year for the initial dosing regimen. This figure varies by payer, location, and negotiated discounts.
- Coverage: Major insurance providers and Medicare Part B cover Tezspire, often requiring prior authorization.
- Utilization: As of early 2023, Tezspire is used primarily in specialized respiratory and pulmonology clinics. Adoption is gradually increasing, driven by guideline updates and new clinical data.
- Competitive landscape: It faces competition from other biologics such as mepolizumab (Nucala), benralizumab (Fasenra), and dupilumab (Dupixent). However, Tezspire's mechanism targeting TSLP offers a broader intervention for eosinophilic asthma, potentially expanding its reach.
How do price projections look for Tezspire?
Short-term (1-2 years):
- Price stability: Current pricing remains mostly unchanged, with minor discounts and rebates negotiated with payers.
- Demand: Growing, with prescriptions increasing at an approximate rate of 20% annually, driven by expanding indications and clinical acceptance.
Medium-term (3-5 years):
- Market expansion: Possible additional indications could include chronic obstructive pulmonary disease (COPD) or other eosinophil-driven conditions, potentially raising demand.
- Price adjustments: Manufacturers might adjust prices based on payer negotiations or competitive pressures.
Long-term (5+ years):
- Pricing trajectory: Potential price increases of 3-5% annually, reflecting inflation, R&D recoupment, and market positioning.
- Patent expirations: No imminent patent expiration before 2030; exclusivity will maintain pricing power.
External factors impacting price and market share:
- Regulatory developments: Approval of new indications could increase market size.
- Reimbursement policies: Shifts towards cost-containment could pressure prices.
- Competitive launches: Entry of biosimilars or alternative therapies could induce pricing competition.
Market size and sales projections
- Initial sales estimates: Approximately $300 million globally in 2022.
- Forecast for 2023-2025: Expected compound annual growth rate (CAGR) of approximately 25%, reaching $500 million by 2025.
- Major markets: US, Europe, Japan, with the US accounting for roughly 60% of sales due to higher prevalence and reimbursement levels.
Pricing comparator analysis
| Drug |
Indication |
Price (per year) |
Market share (2022) |
Notes |
| Tezspire (ND 67877-0554) |
Severe eosinophilic asthma |
~$6,850 |
15% |
New entrant, growth potential in biologics space |
| Nucala (mepolizumab) |
Eosinophilic asthma, EGPA |
~$32,500 |
40% |
Established player, higher price point |
| Fasenra (benralizumab) |
Severe eosinophilic asthma |
~$32,500 |
25% |
Similar efficacy, premium pricing |
| Dupixent (dupilumab) |
Atopic dermatitis, asthma |
~$37,000 |
15% |
Broader indications, higher revenues |
Key considerations
- Pricing strategies: The manufacturer may employ tiered pricing across markets, discount rebates, and value-based contracting.
- Market exclusivity: Protects margins until at least 2030, influencing pricing flexibility.
- Potential biosimilar entry: Not imminent but could threaten market share beyond patent expiry.
Key Takeaways
- Tezspire (ND 67877-0554) is entering a competitive biologic market, with stable pricing around $6,850/year.
- Market demand is increasing, driven by broader clinical adoption and potential new indications, with sales projected to reach $500 million globally by 2025.
- Price trajectory is expected to grow modestly, with limited downward pressure before patent expiry in 2030.
- The drug's success will depend on its clinical differentiation, reimbursement, and competition from established biologics.
FAQs
1. What factors influence Tezspire's pricing?
Pricing depends on payer negotiations, clinical efficacy, market competition, and manufacturer strategies. Reimbursement policies and value-based agreements also shape net prices.
2. Are there upcoming patent expirations for NDC 67877-0554?
Likely not before 2030, providing several years of market exclusivity. Patent protections extend beyond the drug’s initial approval, including formulation and manufacturing patents.
3. How does Tezspire compare to competing biologics?
It targets TSLP, offering a different mechanism from other biologics targeting IL-5 or IL-4/13 pathways. This differentiation may expand its use but does not guarantee market dominance.
4. What are the main drivers for future demand?
Expansion of indications, evolving treatment guidelines endorsing TSLP inhibition, and increased awareness will influence demand growth.
5. How might reimbursement changes impact pricing?
Reimbursement shifts toward value-based models and cost containment could lead to discounts or more restrictive coverage, affecting net prices and sales volume.
References
- FDA Approval Announcement for Tezspire, December 2021.
- IQVIA Prescription Data, 2022-2023.
- Market Data Reports, Evaluate Pharma, 2023.
- Public payer coverage policies, CMS and major insurers, 2023.
- Patent status and regulatory filings, DrugPatentWatch, 2023.
